 Pancreatic Neoplasms
"Pancreatic Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
| Descriptor ID |
D010190
|
| MeSH Number(s) |
C04.588.274.761 C04.588.322.421 C06.301.761 C06.689.667 C19.344.421
|
| Concept/Terms |
Pancreatic Neoplasms- Pancreatic Neoplasms
- Neoplasm, Pancreatic
- Pancreatic Neoplasm
- Neoplasms, Pancreatic
- Pancreas Neoplasms
- Neoplasm, Pancreas
- Neoplasms, Pancreas
- Pancreas Neoplasm
Cancer of Pancreas- Cancer of Pancreas
- Pancreas Cancers
- Pancreas Cancer
- Cancer, Pancreas
- Cancers, Pancreas
- Pancreatic Cancer
- Cancer, Pancreatic
- Cancers, Pancreatic
- Pancreatic Cancers
- Cancer of the Pancreas
|
Below are MeSH descriptors whose meaning is more general than "Pancreatic Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Pancreatic Neoplasms".
This graph shows the total number of publications written about "Pancreatic Neoplasms" by people in this website by year, and whether "Pancreatic Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1981 | 3 | 0 | 3 | | 1982 | 0 | 2 | 2 | | 1983 | 6 | 0 | 6 | | 1984 | 3 | 0 | 3 | | 1985 | 2 | 0 | 2 | | 1986 | 4 | 0 | 4 | | 1987 | 1 | 4 | 5 | | 1988 | 1 | 0 | 1 | | 1989 | 1 | 0 | 1 | | 1990 | 3 | 0 | 3 | | 1991 | 1 | 0 | 1 | | 1992 | 6 | 1 | 7 | | 1993 | 4 | 0 | 4 | | 1994 | 8 | 4 | 12 | | 1995 | 5 | 2 | 7 | | 1996 | 2 | 0 | 2 | | 1997 | 2 | 1 | 3 | | 1998 | 2 | 1 | 3 | | 1999 | 5 | 1 | 6 | | 2000 | 2 | 1 | 3 | | 2001 | 5 | 0 | 5 | | 2002 | 7 | 8 | 15 | | 2003 | 3 | 1 | 4 | | 2004 | 7 | 2 | 9 | | 2005 | 23 | 3 | 26 | | 2006 | 14 | 3 | 17 | | 2007 | 20 | 3 | 23 | | 2008 | 19 | 3 | 22 | | 2009 | 22 | 3 | 25 | | 2010 | 24 | 2 | 26 | | 2011 | 19 | 4 | 23 | | 2012 | 11 | 2 | 13 | | 2013 | 23 | 3 | 26 | | 2014 | 24 | 1 | 25 | | 2015 | 18 | 2 | 20 | | 2016 | 36 | 2 | 38 | | 2017 | 24 | 4 | 28 | | 2018 | 21 | 2 | 23 | | 2019 | 25 | 2 | 27 | | 2020 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Pancreatic Neoplasms" by people in Profiles.
-
Schuster B, Junkin M, Kashaf SS, Romero-Calvo I, Kirby K, Matthews J, Weber CR, Rzhetsky A, White KP, Tay S. Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids. Nat Commun. 2020 10 19; 11(1):5271.
-
Vining CC, Kuchta K, Schuitevoerder D, Paterakos P, Berger Y, Roggin KK, Talamonti MS, Hogg ME. Risk factors for complications in patients undergoing pancreaticoduodenectomy: A NSQIP analysis with propensity score matching. J Surg Oncol. 2020 Aug; 122(2):183-194.
-
Chapman CG, Waxman I. EUS-Guided Portal Venous Sampling of Circulating Tumor Cells. Curr Gastroenterol Rep. 2019 Dec 07; 21(12):68.
-
Hammel P, Kindler HL, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Joo S, Yoo HK, Patel N, Golan T. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. Ann Oncol. 2019 12 01; 30(12):1959-1968.
-
Moore PC, Qi JY, Thamsen M, Ghosh R, Peng J, Gliedt MJ, Meza-Acevedo R, Warren RE, Hiniker A, Kim GE, Maly DJ, Backes BJ, Papa FR, Oakes SA. Parallel Signaling through IRE1a and PERK Regulates Pancreatic Neuroendocrine Tumor Growth and Survival. Cancer Res. 2019 12 15; 79(24):6190-6203.
-
Golan T, Locker GY, Kindler HL. Maintenance Olaparib for Metastatic Pancreatic Cancer. Reply. N Engl J Med. 2019 10 10; 381(15):1492-1493.
-
Chivukula SV, Tierney JF, Hertl M, Poirier J, Keutgen XM. Operative resection in early stage pancreatic neuroendocrine tumors in the United States: Are we over- or undertreating patients? Surgery. 2020 01; 167(1):180-186.
-
Savari O, Golab K, Solomina J, Konsur E, Cieply K, Ramachandran S, Tekin Z, Schenck L, Zhang SS, Tibudan M, Posner MC, Witkowski P. Total Pancreatectomy with Islet Autotransplantation for the Ampullary Cancer. A Case Report. J Gastrointest Cancer. 2019 09; 50(3):543-547.
-
Wei AC, Ou FS, Shi Q, Carrero X, O'Reilly EM, Meyerhardt J, Wolff RA, Kindler HL, Evans DB, Deshpande V, Misdraji J, Tamm E, Sahani D, Moore M, Newman E, Merchant N, Berlin J, Goff LW, Pisters P, Posner MC. Perioperative Gemcitabine?+?Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Ann Surg Oncol. 2019 Dec; 26(13):4489-4497.
-
Innocenti F, Jiang C, Sibley AB, Denning S, Etheridge AS, Watson D, Niedzwiecki D, Hatch AJ, Hurwitz HI, Nixon AB, Furukawa Y, Kubo M, Crona DJ, Kindler HL, McLeod HL, Ratain MJ, Owzar K. An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance). Pharmacogenet Genomics. 2019 08; 29(6):123-131.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|